Remove Clinical Supply Remove Drug Development Remove Pharmaceuticals
article thumbnail

[Webinar] How biotech companies can improve clinical supply planning and distrib…

The Pharma Data

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial. .

article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study. . - Fully equipped to support all types of IP administration forms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Overcoming inefficiencies to improve access to cell and gene therapy 

Drug Discovery World

Repercussions of the Covid-19 pandemic The idea that the Covid-19 pandemic dramatically affected the CGT supply chain and upturned CGT manufacturing has dominated the conversation in the biotech sector 3. But now, the increased efficiency is likely making drug development cheaper.

Therapies 130
article thumbnail

AWS helps Pfizer accelerate drug development and clinical manufacturing

The Pharma Data

The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinical supply chain efforts.

article thumbnail

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.